MA47888B1 - Régime de dosage pour agents anti-bcma - Google Patents

Régime de dosage pour agents anti-bcma

Info

Publication number
MA47888B1
MA47888B1 MA47888A MA47888A MA47888B1 MA 47888 B1 MA47888 B1 MA 47888B1 MA 47888 A MA47888 A MA 47888A MA 47888 A MA47888 A MA 47888A MA 47888 B1 MA47888 B1 MA 47888B1
Authority
MA
Morocco
Prior art keywords
bcma
antibody construct
agents
domain
treatment
Prior art date
Application number
MA47888A
Other languages
English (en)
Inventor
Julia Stieglmaier
Birgit Huber
Alexander Minella
Vijay Upreti
Original Assignee
Amgen Inc.
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68581157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA47888(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc., Amgen Research (Munich) Gmbh filed Critical Amgen Inc.
Publication of MA47888B1 publication Critical patent/MA47888B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne le dosage et l'administration d'agents anti-BCMA pour le traitement de néoplasmes positifs au BCMA. Plus spécifiquement, la présente invention concerne une construction d'anticorps comprenant un premier domaine qui se lie au BCMA, un deuxième domaine qui se lie au CD3 et un troisième domaine qui prolonge ou améliore la demi-vie de la construction d'anticorps, destinée à être utilisée dans le traitement ou l'amélioration d'un néoplasme positif au BCMA, la construction d'anticorps étant administrée à une dose spécifiée dans au moins un cycle. De plus, l'invention concerne un procédé de traitement d'un néoplasme positif au BCMA comprenant l'administration d'une dose spécifiée d'une telle construction d'anticorps, et l'utilisation d'une telle construction d'anticorps pour la fabrication d'un médicament pour le traitement d'un néoplasme positif au BCMA.
MA47888A 2019-11-11 2019-11-11 Régime de dosage pour agents anti-bcma MA47888B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19208417.6A EP3819007B1 (fr) 2019-11-11 2019-11-11 Régime de dosage pour agents anti-bcma

Publications (1)

Publication Number Publication Date
MA47888B1 true MA47888B1 (fr) 2024-10-31

Family

ID=68581157

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47888A MA47888B1 (fr) 2019-11-11 2019-11-11 Régime de dosage pour agents anti-bcma

Country Status (20)

Country Link
US (1) US20210139584A1 (fr)
EP (3) EP3819007B1 (fr)
JP (2) JP2022554362A (fr)
AU (1) AU2020381671A1 (fr)
CA (1) CA3155069A1 (fr)
DK (2) DK3819007T3 (fr)
ES (2) ES2987783T3 (fr)
FI (2) FI3819007T3 (fr)
HR (2) HRP20241281T1 (fr)
HU (2) HUE068401T2 (fr)
LT (2) LT3819007T (fr)
MA (1) MA47888B1 (fr)
MX (1) MX2022005628A (fr)
PL (2) PL3819007T3 (fr)
PT (2) PT3819007T (fr)
RS (2) RS65943B1 (fr)
SI (2) SI3819007T1 (fr)
SM (2) SMT202400373T1 (fr)
TW (1) TW202118784A (fr)
WO (1) WO2021094000A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
EP4243936A1 (fr) * 2020-11-10 2023-09-20 Amgen Inc. Procédés d'administration d'une molécule de liaison à bcma x cd3
WO2023098846A1 (fr) * 2021-12-03 2023-06-08 江苏先声药业有限公司 Nanocorps anti-bcma et son utilisation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
CA2569509C (fr) 2004-06-03 2014-08-12 Novimmune S.A. Anticorps anti-cd3 et leurs methodes d'utilisation
EP1940881B1 (fr) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2009127691A1 (fr) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
EP2352765B1 (fr) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Anticorps monocaténaire bispécifique à domaine unique, spécifique d'espèces croisées
EP2493921B1 (fr) 2009-10-30 2018-09-26 Albumedix Ltd Variants d'albumine
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
EP3974453A3 (fr) 2010-11-16 2022-08-03 Amgen Inc. Agents et procédés pour traiter les maladies en corrélation avec l'expression bcma
CA2830660A1 (fr) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Variants de l'albumine
NO2748201T3 (fr) 2011-08-23 2018-05-12
WO2013026837A1 (fr) 2011-08-23 2013-02-28 Roche Glycart Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t.
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2780364A2 (fr) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
MX2018002043A (es) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
IL313507A (en) * 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
PL3796912T3 (pl) 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MA53732A (fr) * 2018-09-28 2022-01-05 Amgen Inc Anticorps dirigés contre bcma soluble
EP3911371A4 (fr) * 2019-01-18 2023-04-26 University of Southern California Méthodes et compositions pour améliorer la sécurité et l'efficacité de thérapies cellulaires
CN119679936A (zh) 2019-06-24 2025-03-25 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
PT3766701T (pt) 2019-07-18 2023-06-26 Barberan Latorre Jesus Francisco Cabeça, máquina e método de impressão digital em substratos
CN115279459A (zh) 2019-11-05 2022-11-01 百时美施贵宝公司 使用针对bcma和cd3的抗体的治疗方法
MX2023003041A (es) * 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
EP4243936A1 (fr) * 2020-11-10 2023-09-20 Amgen Inc. Procédés d'administration d'une molécule de liaison à bcma x cd3

Also Published As

Publication number Publication date
WO2021094000A1 (fr) 2021-05-20
HUE066166T2 (hu) 2024-07-28
FI3819007T3 (fi) 2024-09-25
RS65943B1 (sr) 2024-10-31
SI3819007T1 (sl) 2024-10-30
LT3819007T (lt) 2024-10-10
JP2022554362A (ja) 2022-12-28
SMT202400373T1 (it) 2024-11-15
HUE068401T2 (hu) 2024-12-28
EP3819007B1 (fr) 2024-07-10
CA3155069A1 (fr) 2021-05-20
EP4058148B1 (fr) 2024-03-13
PT3819007T (pt) 2024-09-20
ES2987783T3 (es) 2024-11-18
DK3819007T3 (da) 2024-09-30
LT4058148T (lt) 2024-05-27
DK4058148T3 (da) 2024-05-06
PT4058148T (pt) 2024-05-03
SMT202400165T1 (it) 2024-05-14
EP4058148A1 (fr) 2022-09-21
HRP20240553T1 (hr) 2024-07-05
EP4424709A2 (fr) 2024-09-04
DK4058148T5 (da) 2024-07-22
US20210139584A1 (en) 2021-05-13
PL3819007T3 (pl) 2024-11-18
ES2987070T3 (es) 2024-11-13
JP2025170264A (ja) 2025-11-18
MX2022005628A (es) 2022-06-14
HRP20241281T1 (hr) 2024-12-06
PL4058148T3 (pl) 2024-09-16
TW202118784A (zh) 2021-05-16
AU2020381671A1 (en) 2022-03-31
RS65581B1 (sr) 2024-06-28
EP3819007A1 (fr) 2021-05-12
FI4058148T3 (fi) 2024-05-06
SI4058148T1 (sl) 2024-06-28
EP4424709A3 (fr) 2024-12-11

Similar Documents

Publication Publication Date Title
MA47888B1 (fr) Régime de dosage pour agents anti-bcma
Landovitz et al. Cabotegravir for HIV prevention in cisgender men and transgender women
Illouz et al. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors
Raffaelli et al. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
Cannon et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Hoffmann et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
EP4174091A4 (fr) Anticorps monocaténaire anti-cd44 et son utilisation dans la préparation d'un médicament pour le traitement d'une tumeur
Fogari et al. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring
El‐Shabrawi et al. Shortened 8 weeks course of dual sofosbuvir/daclatasvir therapy in adolescent patients, with chronic hepatitis C infection
FR2445146A1 (fr) Medicament a prise orale contenant une substance inhibitrice de l'inflammation et un ou plusieurs phospholipides
Blazek et al. Novel therapies on the horizon of hypertension management
Song et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
Yataba et al. Efficacy of S-flurbiprofen plaster in knee osteoarthritis treatment: results from a phase III, randomized, active-controlled, adequate, and well-controlled trial
Husni et al. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Franchi et al. Effects of methylnaltrexone on ticagrelor-induced antiplatelet effects in coronary artery disease patients treated with morphine
Winter et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects
MA37317B1 (fr) Formulation d'anticorps il-17
Shah et al. Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
Kosmas et al. Therapeutic management of hyperlipoproteinemia (a)
Generini et al. Estrogens and neuropeptides in Raynaud's phenomenon
DE602004009449D1 (de) Behandlung von entzug
Ankrom et al. Investigation of pharmacokinetic interactions between doravirine and elbasvir-grazoprevir and ledipasvir-sofosbuvir
Nakano et al. A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
Mariette et al. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes